|
[Related PubMed/MEDLINE]
Total Number of Papers: 25
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Exosomal Circ-MEMO1 Promotes the Progression and Aerobic Glycolysis of Non-small Cell Lung Cancer Through Targeting MiR-101-3p/KRAS Axis. |
3'UTR, circ-MEMO1, exo-circ-MEMO1, GM130, HK2, LDHA, miR-101-3p, mRNA, NSCLC, qRT-PCR, RIP |
| 2 |
2020 |
Mediastinal Germ Cell Tumor and Acute Megakaryoblastic Leukemia With Co-occurring KRAS Mutation and Complex Cytogenetics. |
AMKL, NSGCTs, PTEN, TP53 |
| 3 |
2020 |
Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. |
BRAF, CRC, MSI, MST |
| 4 |
2019 |
Different mutation profiles between epithelium and stroma in endometriosis and normal endometrium. |
PIK3CA |
| 5 |
2019 |
Downregulation of miR‑143 modulates KRAS expression in colorectal carcinoma cells. |
miRs |
| 6 |
2019 |
Expression and role of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues. |
EGFR |
| 7 |
2019 |
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer. |
APC, ATM, BRCA1, BRCA2, ERBB2, HR, MMR, PMS2, SNVs, TP53 |
| 8 |
2019 |
Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K. |
EGFR |
| 9 |
2019 |
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer. |
NSCLC, PFS, PIK3CA, TP53 |
| 10 |
2019 |
Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report. |
EGFR, non-SCLC, TKIs |
| 11 |
2018 |
Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells. |
BRD4 |
| 12 |
2018 |
Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis. |
IDH1, iNOS, MTH1, MUTYH, TP53, UC |
| 13 |
2018 |
Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. |
HCC, ICC, NRAS |
| 14 |
2018 |
The clinical significance of COL5A2 in patients with bladder cancer: A retrospective analysis of bladder cancer gene expression data. |
--- |
| 15 |
2017 |
A case report of tongue metastasis from lung squamous cell carcinoma and literature review. |
PIK3CA, TP53 |
| 16 |
2017 |
All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. |
FOSL1 |
| 17 |
2017 |
Coffee reduces KRAS expression in Caco-2 human colon carcinoma cells via regulation of miRNAs. |
miR |
| 18 |
2017 |
Colorectal cancer in cases of multiple primary cancers: Clinical features of 59 cases and point mutation analyses. |
CRC, MPCC |
| 19 |
2017 |
Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis. |
1- sensitivity, AUC, ctDNA, DOR, FN, FP, NLR, PLR, TN, TP |
| 20 |
2017 |
Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome. |
ASXL1, MDS, NRAS, TP53 |
| 21 |
2017 |
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency. |
BRAF, ECHS1, HRAS, IEM, MACS, MAP, NRAS, PTPN11, RAF1, RIN2, SOS2, TALDO1 |
| 22 |
2017 |
Wild‑type blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS. |
WTB |
| 23 |
2016 |
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. |
cfDNA, NSCLC, OS, PFS |
| 24 |
2016 |
Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors. |
BRAF, HPV, HSIL, SCC |
| 25 |
2016 |
Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection. |
BRAF, CRC |
|
A Search Service for Abbreviation / Long Form
